Samsung Biologics said on Monday it had made an all-cash offer worth about $1.8 billion for Switzerland's PolyPeptide Group, according to CNBC.
Key facts
- Samsung Biologics is acquiring Switzerland's PolyPeptide Group.
- The all-cash offer is worth 1.46 billion Swiss francs (about $1.8 billion).
- The deal is also valued at 2.7 trillion won, per CNBC.
- The announcement was made on Monday, according to CNBC.
South Korea’s Samsung Biologics said on Monday that it had made an all-cash bid for Switzerland’s PolyPeptide Group, according to CNBC. The offer is valued at 1.46 billion Swiss francs, or roughly $1.8 billion.
CNBC reported that the deal amounts to 2.7 trillion won, underscoring the scale of the proposed acquisition for the South Korean company.
The offer is structured as an all-cash transaction, according to CNBC, meaning Samsung Biologics is proposing to pay shareholders in cash rather than in stock or a mix of cash and shares.
PolyPeptide Group is based in Switzerland. The reported bid places a substantial valuation on the company as Samsung Biologics moves to expand through the acquisition.
The details available so far come from CNBC’s reporting published on July 20, 2026. Further specifics of the transaction were not included in the sources provided.
Why it matters
A cross-border, all-cash deal of this size signals continued consolidation in the pharmaceutical and biologics sector. For investors and patients alike, moves by major players like Samsung Biologics can reshape manufacturing capacity and competition in the industry.
Frequently asked questions
How much is Samsung Biologics offering for PolyPeptide Group?
Samsung Biologics made an all-cash bid of 1.46 billion Swiss francs, or about $1.8 billion, according to CNBC. CNBC also reported the deal at 2.7 trillion won.
Is the deal being paid in cash or stock?
According to CNBC, the offer is an all-cash bid.
When was the deal announced?
Samsung Biologics said it had made the offer on Monday, with CNBC's reporting published on July 20, 2026.